News Vertex is smarting from a pain portfolio setback Shares in Vertex Pharma have come under pressure after one of its non-opioid pain candidates failed to move the needle in a mid-stage trial.
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
News Algiax non-opioid drug works in chronic neuropathic pain A GABA-targeting drug developed by German Biotech Algiax has shown proof of concept in a chronic neuropathic trial trial.
News Vertex bags FDA okay for its non-opioid pain drug Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.